Back to Search
HEATHER WAKELEE, MD
MD
Medical Oncology Physician
NPI: 1720137094IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
A63195(CA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
Class of 1996
Research & Publications (20)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
PMID 19633048·Ann Oncol·2010
3-trial
Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
PMID 19544694·Oncology (Williston Park)·2009
8-other
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
PMID 19073517·Clin Lung Cancer·2008
6-review
Adjuvant chemotherapy for resected non-small cell lung cancer.
PMID 19038728·Semin Thorac Cardiovasc Surg·2008
6-review
Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
PMID 18520292·J Thorac Oncol·2008
6-review
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer.
PMID 18282352·Clin Lung Cancer·2008
6-review
Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
PMID 17405898·Oncologist·2007
6-review
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.
PMID 16870041·Clin Lung Cancer·2006
6-review
Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.
PMID 17409897·J Thorac Oncol·2006
2-rct
Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
PMID 16604529·Cancer·2006
4-observational
Optimizing first-line treatment options for patients with advanced NSCLC.
PMID 16368866·Oncologist·2005
6-review
Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
PMID 16159420·Clin Lung Cancer·2005
6-review
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
PMID 16159417·Clin Lung Cancer·2005
6-review
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.
PMID 15893008·Lung Cancer·2005
3-trial
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
PMID 15868380·Invest New Drugs·2005
3-trial
Docetaxel in advanced non-small cell lung cancer.
PMID 15757434·Expert Rev Anticancer Ther·2005
6-review
Novel approaches for the treatment of small cell lung cancer.
PMID 15094184·Hematol Oncol Clin North Am·2004
6-review
Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
PMID 19513949·Curr Opin Investig Drugs·2009
7-preclinical
Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California.
PMID 19622719·Cancer Epidemiol Biomarkers Prev·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 875 Blake Wilbur Dr, Stanford Cancer Center
Stanford, CA 94305 - Phone
- (650) 723-9094
Quick Facts
- NPI
- 1720137094
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 30
- Publications
- 20
Are you this provider?
Claim Your Profile